Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma
| Autor: | Hidemi Goto, Isao Nakano, Kazuhiko Hayashi, Yoji Ishizu, Tetsuya Ishikawa, Teiji Kuzuya, Takashi Honda, Yoshiki Hirooka, Masatoshi Ishigami |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Niacinamide Oncology Sorafenib Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Lung Neoplasms Time Factors Fever Contrast Media Antineoplastic Agents urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Text mining Internal medicine medicine Humans heterocyclic compounds In patient neoplasms Aged Retrospective Studies Aged 80 and over business.industry Phenylurea Compounds Antitumor response General Medicine Middle Aged medicine.disease female genital diseases and pregnancy complications digestive system diseases Treatment efficacy Survival Rate Treatment Outcome 030220 oncology & carcinogenesis Hepatocellular carcinoma Female 030211 gastroenterology & hepatology Tomography X-Ray Computed business medicine.drug |
| Zdroj: | Oncology. 91:261-266 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Objectives: The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC). Methods: One hundred and two patients with advanced HCC were enrolled in this study. We retrospectively compared patients with fever (more than 38°C) within 2 weeks after the start of sorafenib therapy (fever group, n = 34) and patients without fever (non-fever group, n = 68) in terms of survival, best antitumor response, and change in intratumor blood on contrast-enhanced computed tomography (CE-CT) after 2 weeks of sorafenib therapy. Results: Fever was the only significant and independent predictor of better outcomes (hazard ratio, 0.517; 95% confidence interval, 0.319-0.838; p = 0.0071). In the fever group, the partial response rate, the disease control rate, and the rate of disappearance of arterial tumor enhancement on CE-CT after 2 weeks of sorafenib therapy were significantly higher than those in the non-fever group (38.2 vs. 5.9%, respectively, p = 0.0001; 85.3 vs. 60.3%, respectively, p = 0.0103; 76.5 vs. 35.3%, respectively, p < 0.0001). Conclusions: Fever within 2 weeks after the start of sorafenib therapy may be a useful predictor of a favorable treatment response in patients with advanced HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|